FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387263131> ?p ?o ?g. }

• W4387263131 abstract "<p>Endocrine treatment shapes tumor immune microenvironment in primary hormone receptor–positive breast cancer. <b>A–F,</b> Digital spatial profiling proteomic levels (log₂ expression levels) of immune cell surface markers ranking from highest to lowest expression. <b>A,</b> Baseline levels within the immune regions in tumors from patients who received endocrine therapy [F(<a href=#bib11 target=_blank>11</a>, 312) = 57.1, <i>P</i> < 2e−16, one-way ANOVA]. <b>B,</b> Protein expression levels within the immune regions after 2 weeks of endocrine treatment [F(<a href=#bib11 target=_blank>11</a>, 276) = 41.7, <i>P</i> < 2e−16, one-way ANOVA]. <b>C,</b> Protein expression levels within the immune regions after 24 weeks of endocrine treatment at the time of surgery [F(<a href=#bib11 target=_blank>11, 1212</a>) = 305.2, <i>P</i> < 2e−16, one-way ANOVA]. <b>D,</b> Baseline levels within the invasive epithelial cell regions in tumors from patients who received endocrine therapy [F (<a href=#bib11 target=_blank>11</a>, 732) = 126.3, <i>P</i> < 2e−16, one-way ANOVA]. <b>E,</b> Protein expression levels within the invasive epithelial regions after 2 weeks of endocrine treatment (<i>P</i> < 2e−16, one-way ANOVA). <b>F,</b> Protein expression levels within the invasive epithelial cell regions after 24 weeks of endocrine treatment at the time of surgery (<i>P</i> < 2e−16, one-way ANOVA). Boxplots show median, 25th, and 75th percentiles as boxes, the minimum of the 75th percentile + 1.5 × IQR, and the maximum observation as the upper whisker and the maximum of the 25th percentile −1.5 × IQR and the minimum observation as the lower whisker. <b>G,</b> Trajectory plot of TIL fractions between baseline and 2 weeks. <i>P</i>-val, <i>P</i> value (paired Wilcoxon signed-rank test with continuity correction). <b>H,</b> Trajectory plot of TIL fractions between 2 weeks and surgery for all patients given endocrine treatment that have TIL observations at all three time points. Each trajectory corresponds to a single patient. <i>P</i>-val, <i>P</i> value (paired Wilcoxon signed-rank test with continuity correction). <b>I,</b> GSVA of the T-cell accumulation gene set in primary ER⁺ breast cancer biopsies from pre- and post-neoadjuvant AI treatment. <b>J,</b> Enrichment plot of the top-ranked gene set (estrogen response) enriched in the ESR1 highest (fourth quartile) versus ESR1 lowest (first quartile) ER–positive breast cancer samples from the TCGA cohort. <b>K–M,</b> GSVA of RNA-seq from the ER–positive breast cancer samples from TCGA divided into quartiles based on ESR1 mRNA levels testing the enrichment score (<i>y</i>-axis) for signatures of immune-checkpoint blockade (ICB) resistance (<b>K</b>), T-regulatory (Treg) accumulation (<b>L</b>), and cytotoxic T-cell accumulation (<b>M</b>). Comparison between the quartiles was done with a <i>t</i> test. <i>N</i>, number of patients included in the corresponding analysis.</p>" @default.
• W4387263131 created "2023-10-03" @default.
• W4387263131 creator A5001315712 @default.
• W4387263131 creator A5005699273 @default.
• W4387263131 creator A5006077440 @default.
• W4387263131 creator A5006906416 @default.
• W4387263131 creator A5008111913 @default.
• W4387263131 creator A5008682981 @default.
• W4387263131 creator A5010234110 @default.
• W4387263131 creator A5012991748 @default.
• W4387263131 creator A5017174066 @default.
• W4387263131 creator A5020035024 @default.
• W4387263131 creator A5022422153 @default.
• W4387263131 creator A5024648766 @default.
• W4387263131 creator A5026132340 @default.
• W4387263131 creator A5027326315 @default.
• W4387263131 creator A5029062544 @default.
• W4387263131 creator A5030750380 @default.
• W4387263131 creator A5037645425 @default.
• W4387263131 creator A5039071000 @default.
• W4387263131 creator A5041427080 @default.
• W4387263131 creator A5042549348 @default.
• W4387263131 creator A5043143519 @default.
• W4387263131 creator A5047701430 @default.
• W4387263131 creator A5051714606 @default.
• W4387263131 creator A5053368670 @default.
• W4387263131 creator A5053695772 @default.
• W4387263131 creator A5053819517 @default.
• W4387263131 creator A5055038052 @default.
• W4387263131 creator A5055378234 @default.
• W4387263131 creator A5059400884 @default.
• W4387263131 creator A5060353514 @default.
• W4387263131 creator A5062515397 @default.
• W4387263131 creator A5064188148 @default.
• W4387263131 creator A5066070097 @default.
• W4387263131 creator A5069056507 @default.
• W4387263131 creator A5069182089 @default.
• W4387263131 creator A5081025221 @default.
• W4387263131 creator A5082128924 @default.
• W4387263131 creator A5083901548 @default.
• W4387263131 creator A5085458148 @default.
• W4387263131 creator A5090611170 @default.
• W4387263131 creator A5016265992 @default.
• W4387263131 date "2023-10-02" @default.
• W4387263131 modified "2023-10-03" @default.
• W4387263131 title "Figure 2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer" @default.
• W4387263131 doi "https://doi.org/10.1158/0008-5472.24229153.v1" @default.
• W4387263131 hasPublicationYear "2023" @default.
• W4387263131 type Work @default.
• W4387263131 citedByCount "0" @default.
• W4387263131 crossrefType "posted-content" @default.
• W4387263131 hasAuthorship W4387263131A5001315712 @default.
• W4387263131 hasAuthorship W4387263131A5005699273 @default.
• W4387263131 hasAuthorship W4387263131A5006077440 @default.
• W4387263131 hasAuthorship W4387263131A5006906416 @default.
• W4387263131 hasAuthorship W4387263131A5008111913 @default.
• W4387263131 hasAuthorship W4387263131A5008682981 @default.
• W4387263131 hasAuthorship W4387263131A5010234110 @default.
• W4387263131 hasAuthorship W4387263131A5012991748 @default.
• W4387263131 hasAuthorship W4387263131A5016265992 @default.
• W4387263131 hasAuthorship W4387263131A5017174066 @default.
• W4387263131 hasAuthorship W4387263131A5020035024 @default.
• W4387263131 hasAuthorship W4387263131A5022422153 @default.
• W4387263131 hasAuthorship W4387263131A5024648766 @default.
• W4387263131 hasAuthorship W4387263131A5026132340 @default.
• W4387263131 hasAuthorship W4387263131A5027326315 @default.
• W4387263131 hasAuthorship W4387263131A5029062544 @default.
• W4387263131 hasAuthorship W4387263131A5030750380 @default.
• W4387263131 hasAuthorship W4387263131A5037645425 @default.
• W4387263131 hasAuthorship W4387263131A5039071000 @default.
• W4387263131 hasAuthorship W4387263131A5041427080 @default.
• W4387263131 hasAuthorship W4387263131A5042549348 @default.
• W4387263131 hasAuthorship W4387263131A5043143519 @default.
• W4387263131 hasAuthorship W4387263131A5047701430 @default.
• W4387263131 hasAuthorship W4387263131A5051714606 @default.
• W4387263131 hasAuthorship W4387263131A5053368670 @default.
• W4387263131 hasAuthorship W4387263131A5053695772 @default.
• W4387263131 hasAuthorship W4387263131A5053819517 @default.
• W4387263131 hasAuthorship W4387263131A5055038052 @default.
• W4387263131 hasAuthorship W4387263131A5055378234 @default.
• W4387263131 hasAuthorship W4387263131A5059400884 @default.
• W4387263131 hasAuthorship W4387263131A5060353514 @default.
• W4387263131 hasAuthorship W4387263131A5062515397 @default.
• W4387263131 hasAuthorship W4387263131A5064188148 @default.
• W4387263131 hasAuthorship W4387263131A5066070097 @default.
• W4387263131 hasAuthorship W4387263131A5069056507 @default.
• W4387263131 hasAuthorship W4387263131A5069182089 @default.
• W4387263131 hasAuthorship W4387263131A5081025221 @default.
• W4387263131 hasAuthorship W4387263131A5082128924 @default.
• W4387263131 hasAuthorship W4387263131A5083901548 @default.
• W4387263131 hasAuthorship W4387263131A5085458148 @default.
• W4387263131 hasAuthorship W4387263131A5090611170 @default.
• W4387263131 hasBestOaLocation W43872631311 @default.
• W4387263131 hasConcept C126322002 @default.
• W4387263131 hasConcept C134018914 @default.
• W4387263131 hasConcept C159654299 @default.
• W4387263131 hasConcept C170493617 @default.
• W4387263131 hasConcept C203014093 @default.
• W4387263131 hasConcept C2778453870 @default.
• W4387263131 hasConcept C46699223 @default.

• next